Vaccine-related HPV genotypes in women with and without cervical cancer in Mozambique: burden and potential for prevention.
Knowledge about the burden of Human Papillomavirus (HPV) infections in Sub-Saharan Africa is very limited. We collected cervical samples from 262 women from the general population and 241 tumor samples from women with invasive cervical cancer in Mozambique and tested them for HPV genotyping by the SPF(10)-LiPA(25) PCR system. Among the 195 women without cervical abnormalities by cytology HPV prevalence was 75.9%. In this group of women, the most frequently identified HPV types among HPV-positive women were in descending order of frequency: HPV51 (23.6%), HPV35 (19.6%), HPV18 (14.2%), HPV31 (13.5%) and HPV52 (12.8%). In women with cervical cancer HPV DNA detection was 100%. The type-specific distribution of the most frequent types in descending order of frequency was: HPV16 (47.0%), HPV18 (31.3%), HPV51 (14.8%), HPV52 (14.3%), HPV45 (12.6%), HPV35 (10.4%), HPV33 (4.8%) and HPV31 (2.6%). HPVs 16/18 and HPVs 16/18/31/45 were detected in 71.7% and 80.9% of cervical cancer tissue, respectively. While HPVs 51 and 35 were the two most common types in cytologically normal women in Mozambique, HPVs 16 and 18 remained the two most frequently identified types in cervical cancer. The introduction of an efficacious HPV 16/18 vaccine could potentially prevent the occurrence of 72% of cervical cancer cases and up to 81% of the cases if full cross-protection against HPVs 31 and 45 is assumed.
Castellsagué
Xavier
X
IDIBELL, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Barcelona, Spain. xcastellsague@iconcologia.net
Klaustermeier
Joellen
J
Carrilho
Carla
C
Albero
Ginesa
G
Sacarlal
Jahit
J
Quint
Wim
W
Kleter
Bernhard
B
Lloveras
Belen
B
Ismail
Mamudo Rafik
MR
de Sanjosé
Silvia
S
Bosch
F Xavier
FX
Alonso
Pedro
P
Menéndez
Clara
C
D000328:Adult; D052685:Alphapapillomavirus / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification*; D017281:Cost of Illness; D004279:DNA, Viral / Q000302:isolation & purification; D005260:Female; D005838:Genotype; D052162:Human papillomavirus 16 / Q000302:isolation & purification; D052161:Human papillomavirus 18 / Q000302:isolation & purification; D006801:Humans; D008875:Middle Aged; D009073:Mozambique / Q000453:epidemiology; D030361:Papillomavirus Infections / Q000150:complications* / Q000821:virology; D053918:Papillomavirus Vaccines / Q000008:administration & dosage*; D011322:Primary Prevention / Q000379:methods; D014412:Tumor Virus Infections / Q000150:complications* / Q000821:virology; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology* / Q000235:genetics / Q000276:immunology / Q000517:prevention & control*
D004279:DNA, Viral; D053918:Papillomavirus Vaccines